Table 2

Univariate analysis of prognostic indicators

FactorNo. of casesDisease-free timePDeath from breast cancerP
Mean survival (y)SEMean survival (y)SE
Size of tumor0.80.825
 <2.0 cm2110.112.3113.62.41
 2.0–5.0 cm5411.761.4913.21.47
 >5.0 cm109.393.2103.04
Nodal status 0.00269 0.00275
 Positive498.231.4410.41.55
 Negative3616.511.8517.71.77
ERa0.1510.139
 Positive3312.51.7313.61.59
 Negative5310.51.5712.51.59
PR0.4710.588
 Positive259.682.0811.11.99
 Negative4712.031.6313.71.59
ERBB20.3180.412
 Positive159.252.6410.62.6
 Negative6712.451.46141.41
CK140.1930.385
 Positive4312.71.7314.21.67
 Negative4310.51.7212.51.71
CK19 0.0209 0.0402
 Positive8312.381.2914.11.261
 Negative31.170.3952.720.784
CGH alterations0.8880.931
 0813.354.3513.94.17
 1–105211.981.5413.91.52
 11–20209.532.2611.92.43
 21 or more69.533.5410.53.21
Gain of 1q 0.0469 0.043
 Present186.632.167.911.96
 Absent6713.421.4415.321.41
Loss of 3p 0.00339 0.00244
 Present102.541.013.50.954
 Absent6813.261.4315.21.392
Loss of 4p 0.00397 0.0423
 Present72.571.315.763.01
 Absent7512.821.3614.431.32
Gain of 6p 0.0183 0.0408
 Present72.441.333.641.21
 Absent7412.341.3714.191.34
Loss of 8p0.0032 0.0186
 Present72.341.513.551.37
 Absent7212.681.3914.221.31
CGH profile0.175 0.0414
 Cluster 1238.192.068.831.98
 All others6313.081.4815.21.44
  • NOTE. Statistical significance was calculated for disease-free and overall survival between different stratifications of clinicopathological, immunohistochemical, and CGH data by the log-rank test. Significant factors (P < 0.05) are highlighted in italics.

  • a ER, estrogen receptor; PR, progesterone receptor; CGH, comparative genomic hybridization.